よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (44 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
別冊
112. Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Community-acquired Acinetobacter
infections. Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):857-868.
113. Asai N, Sakanashi D, Suematsu H. et al. Clinical manifestations and risk factors of
community-onset Acinetobacter species pneumonia in Japan; case control study in a single
institute in Japan. J Infect Chemother. 2019 Aug;25(8):639-642.
114. WHO priority pathogens list for R&D of new antibiotics. 2017. at
https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-newantibiotics-are-urgently-needed.)
115. 韓国からの持ち込み例を端緒とした多剤耐性 Acinetobacter baumannii によるアウトブレイ
ク事例 IASR Vol. 31 p. 197-198: 2010 年 7 月号. 2010. at
http://idsc.nih.go.jp/iasr/31/365/dj3654.html.)
116. Tojo M, Mawatari M, Hayakawa K. et al. Multidrug-resistant Acinetobactor baumannii isolated
from a traveler returned from Brunei. J Infect Chemother. 2015 Mar;21(3):212-214.
117. 医療機関における海外からの高度薬剤耐性菌の持ち込み対策に関するガイダンス, DCC.
2019. at https://dcc.ncgm.go.jp/prevention/resource/resource05.pdf.)
118. 厚生労働省 薬剤耐性アシネトバクター感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-140912-4.html.)
119. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial
bloodstream infections caused by Acinetobacter species in United States hospitals: clinical
features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis. 2000
Sep;31(7):690-697.
120. Martin-Aspas A, Guerrero-Sanchez FM, Garcia-Colchero F, Rodriguez-Roca S, GironGonzalez JA. Differential characteristics of Acinetobacter baumannii colonization and
infection: risk factors, clinical picture, and mortality. Infect Drug Resist. 2018 Jun;11:861-872.
121. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis. 2010
Jul;51(1):79-84.
122. Penwell WF, Shapiro AB, Giacobbe RA. et al. Molecular mechanisms of sulbactam
antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob
Agents Chemother. 2015 Mar;59(3):1680-1689.
123. Isler B, Doi Y, Bonomo RA, Paterson DL. New Treatment Options against CarbapenemResistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2019
Dec;63(1):e01110-18.
124. Chang YY, Yang YS, Wu SL. et al. Comparison of Cefepime-Cefpirome and Carbapenem
Therapy for Acinetobacter Bloodstream Infection in a Multicenter Study. Antimicrob Agents
Chemother. 2020 May;64(6):e02392-19.
125. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter
baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019 Aug;25(8):951-957.
126. Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of
multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec;59 Suppl 6:S374-80.
44
第三版
別冊
112. Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Community-acquired Acinetobacter
infections. Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):857-868.
113. Asai N, Sakanashi D, Suematsu H. et al. Clinical manifestations and risk factors of
community-onset Acinetobacter species pneumonia in Japan; case control study in a single
institute in Japan. J Infect Chemother. 2019 Aug;25(8):639-642.
114. WHO priority pathogens list for R&D of new antibiotics. 2017. at
https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-newantibiotics-are-urgently-needed.)
115. 韓国からの持ち込み例を端緒とした多剤耐性 Acinetobacter baumannii によるアウトブレイ
ク事例 IASR Vol. 31 p. 197-198: 2010 年 7 月号. 2010. at
http://idsc.nih.go.jp/iasr/31/365/dj3654.html.)
116. Tojo M, Mawatari M, Hayakawa K. et al. Multidrug-resistant Acinetobactor baumannii isolated
from a traveler returned from Brunei. J Infect Chemother. 2015 Mar;21(3):212-214.
117. 医療機関における海外からの高度薬剤耐性菌の持ち込み対策に関するガイダンス, DCC.
2019. at https://dcc.ncgm.go.jp/prevention/resource/resource05.pdf.)
118. 厚生労働省 薬剤耐性アシネトバクター感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-140912-4.html.)
119. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial
bloodstream infections caused by Acinetobacter species in United States hospitals: clinical
features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis. 2000
Sep;31(7):690-697.
120. Martin-Aspas A, Guerrero-Sanchez FM, Garcia-Colchero F, Rodriguez-Roca S, GironGonzalez JA. Differential characteristics of Acinetobacter baumannii colonization and
infection: risk factors, clinical picture, and mortality. Infect Drug Resist. 2018 Jun;11:861-872.
121. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis. 2010
Jul;51(1):79-84.
122. Penwell WF, Shapiro AB, Giacobbe RA. et al. Molecular mechanisms of sulbactam
antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob
Agents Chemother. 2015 Mar;59(3):1680-1689.
123. Isler B, Doi Y, Bonomo RA, Paterson DL. New Treatment Options against CarbapenemResistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2019
Dec;63(1):e01110-18.
124. Chang YY, Yang YS, Wu SL. et al. Comparison of Cefepime-Cefpirome and Carbapenem
Therapy for Acinetobacter Bloodstream Infection in a Multicenter Study. Antimicrob Agents
Chemother. 2020 May;64(6):e02392-19.
125. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter
baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019 Aug;25(8):951-957.
126. Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of
multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec;59 Suppl 6:S374-80.
44